Globus Medical, Inc. Q4 2025 Earnings Call Summary

Moby Strategic Performance and Operational Drivers. Record Q4 performance was driven by double-digit U.S. Spine growth and ...

Elutia Selects Pete Ligotti as CCO to Lead the Commercial Launch of NXT-41x and Transform Post-Mastectomy Care in the $1.5B U.S. Breast Surgery Market

NXT-41x is Elutia's next-generation antibiotic-eluting biomatrix, built on the Company's validated drug-eluting platform. Elutia is applying that platform in plastic and reconstructive surgery, where ...

Globus Medical Reports Fourth Quarter and Full Year 2025 Results

Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology solutions company, today announced its financial results for the fourth quarter ...

Globus Medical Record Q4 And Synergies Refocus Valuation And Growth Debate

Globus Medical (NYSE:GMED) reported record Q4 and full year results, supported by its U.S. Spine and Trauma businesses and ...
MassDevice

Globus Medical surpasses market expectations, driven by acquisitions

Globus Medical cites successful integration of NuVasive and Nervo and strong domestic spine sales growth as drivers in strong Q4 results.
PharmiWeb

Stem Cell Therapy Market Research Report, Analysis. Demand by Region, Growth, Size, Share and Forecast to 2029

The global stem cell therapy market is projected to experience robust growth, with an expected annual growth rate of 20% by 2029. Key drivers behind this expansion include a favorable investment ...